In San Francisco on August 10, 2026, Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company known as Olema Oncology, disclosed their financial and operational performance for the quarter concluding on June 30, 2026. Olema concentrates on creating, advancing, and marketing targeted treatments primarily for breast cancer.